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Despite several revisions of the TNM lung cancer staging 
system, the N2 descriptor still brings together in one single 
category, a very different group of patients with dissimilar 
overall prognosis, ranging from microscopical/small single 
station N2 to multiple/bulky disease (1,2). At one end of 
this spectrum, the disease appears to be resectable, whilst, 
at the other end, it is obviously unresectable. In patients 
with suspected N2 disease, a preoperative careful staging 
algorithm is therefore fundamental. Thoracic CT scan, 
18F-fludeoxyglucose positron emission tomography (PET-CT 
scan), and possibly, lymph node biopsy (by endobronchial 
ultrasound-EBUS or cervical mediastinoscopy) are the 
common tools currently used to prove mediastinal lymph 
nodal involvement. In general, the prognosis of locally 
advanced neoplasms depends on the importance of nodal 
invasion but generally remains poor, even if in recent studies, 
overall survival could also reach 24 months.
The standard of care for locally advanced non-small cell 
lung cancer (NSCLC) remains concurrent platinum-based 
chemotherapy (CT) and radiotherapy (RT) up to 60–66 Gy (3,4). 
Furthermore, cisplatin-etoposide CT + RT scheme 
demonstrated its superiority compared to pemetrexed-
cisplatin + RT one (5). 
With the discovery of driver genes and the application 
of  target ing drugs ,  pat ients  wi th  advanced lung 
adenocarcinoma have recently acquired a significantly 
prolonged survival (6). However, advances in treating 
advanced stage squamous NSCLC are still inadequate, 
and the overall 5-year survival rate remains unfortunately, 
around 17% (7). Therefore, the development of new 
treatments is urgently needed.
The new advances in the understanding of immunology 
and antitumor immune responses have led to the clinical 
evaluation of new immunotherapies, including vaccination 
approaches and monoclonal antibodies that inhibit immune 
checkpoint pathways. Cancer cells may, in fact, survive even 
in immunocompetent patients, since they acquire tolerance 
mechanisms letting them to escape immune surveillance. 
Recent results demonstrated that so-called releasing the 
brakes (also including the inhibition of immune check-
points) is effective against cancer cells.
One of the most relevant breakthroughs in recent cancer 
therapy is therefore the application of immune checkpoint 
inhibitors in clinical trials. 
The cornerstone of immunotherapy development is 
the knowledge of different process of the T-cell immune 
system activation and, consequently, of the balance between 
inhibitory and activating signals dysregulated by tumor cells. 
Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) 
and programmed death 1 (PD-1) are two examples of 
immune checkpoint pathways involved in controlling T-cell 
immune responses. PD-1 binds to the programmed death 
ligand-1 (PD-L1) and PD-L2, with T-cell proliferation 
reduction, cytokine production alteration and, finally, 
T-cells exhaustion and/or apoptosis induction (8). Once 
they interact with their corresponding ligands, the activity 
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of T cell is inhibited and the immune response to the 
tumor antigen is attenuated, thereby preventing T cell from 
attacking tumor. Moreover, antibodies that block CTLA-4 
and PD-1 receptors and one of their ligands (PD-L1) have 
shown impressive response rates in solid tumors, first in 
melanoma, and subsequently in renal cell carcinoma as well 
as in NSCLC. Currently, two PD-1 inhibitors are available 
in clinical practice for treatment of advanced NSCLC: 
nivolumab and pembrolizumab.
Results of recent clinical trials using nivolumab are 
encouraging: in the NSCLC subgroup of patients [129] 
treated with escalating doses of nivolumab, the objective 
response rate was 17%, with a median response duration of 
74 weeks (range, 6.1–133.9 weeks) (9). In particular, many of 
these patients have been heavily pretreated, and more than 
50% of them received 3 prior CT schedules. Furthermore, 
in  a  phase  II  s ingle-arm tr ia l  (CheckMate  063) , 
patients with advanced-stage NSCLC were treated with 
third-line therapy and beyond: the partial response rate was 
14.5% and 26% of these patients had stable disease. The 
overall survival was 8.2 months, with a 1-year survival of 
approximately 41% (10). In a recent phase II Japanese trial, 
the objective response rate was 25.7% for patients with 
squamous cell NSCLC compared to 19.7% for those with 
non-squamous cell one (11). In addition, in another phase II 
study (CheckMate 153), 824 patients were treated for 1 year 
with nivolumab: the partial response and stable disease rates 
were 12% and 44%, respectively (12). CheckMate 017 study 
was the first who referred the beneficial effect of nivolumab 
assessed by patient-reported outcomes. Those who received 
Nivolumab had greater symptom improvement compared 
to those who were treated with docetaxel. Moreover, the 
time to first disease-related deterioration was longer in the 
nivolumab group (13). Finally, efficacy and safety of single-
agent nivolumab in the first-line therapy was described in 
the CheckMate 012 study. Adverse effects occurred in 71% 
of patients, with the most common of which being fatigue 
(29%), rash (19%), nausea (14%), diarrhea (12%), pruritus 
(12%) and polyarthralgia (10%). The overall response 
rate was 23% and the progression-free survival and overall 
survival were 3.6 and 19.4 months, respectively (14).
Immune-related adverse events (ir-AEs) observed 
with anti PD-1/PD-L1 therapies are usually less severe 
compared to those associated with CTLA4 targeted agents 
(e.g., ipilimumab). Nivolumab demonstrated a better 
safety profile comparing to standard second-line therapy 
in squamous and non-squamous NSCLC (15). Although 
ir-AEs are generally of low grade, these can occur with 
rapid onset, and prompt medical attention and diagnosis are 
paramount to efficiently manage them.
The addition of RT to platinum-based CT improved 
the outcome of advanced-stage NSCLC patients, being 
the current standard of treatment (16); radiochemotherapy 
demonstrated to be superior to RT alone (17). The 
standard dose and volume were historically established 
by the Radiation Therapy Oncology Group (RTOG) 
dose escalation trial 7301 (18). Since then, a number of 
changes in the treatment occurred, including the addition 
of concurrent chemotherapy and the application of three-
dimensional conformal radiation therapy (3DCRT). 
Intensity-modulated RT (IMRT) with definition volumes 
improved by the use of FDG PET-scan has been recently 
proposed, with the aim to increase the local disease control. 
Interestingly, several phase I–II trials showed that with 
concurrent chemoradiation, maximal tolerated dose of 
normo-fractionated radiotherapy was 74 Gy, even if a 
clear demonstration that this regimen may produce better 
results compared to the traditional 60 Gy schedule was not 
achieved (19). Indeed, there was no significant difference 
in terms of grade 3 or worse toxic effects between the 2 
radiotherapy groups; however, more treatment related 
deaths in the high-dose chemoradiotherapy, especially 
resulting from heart toxicity, were observed. Finally, 
adaptive radiotherapy is a promising and feasible perspective 
in several cancers, including NSCLC to increase dose in 
biological target volume defined on 18F-FDG PET/CT 
imaging performed during the course of radiotherapy.
In conclusion, the management of locally advanced 
NSCLC is challenging, especially now, when new CT drugs 
become available. Nivolumab and pembrolizumab raided 
in second-line therapy of squamous cell tumor, but there 
are still unsolved questions: (I) which kind of treatment 
is desirable and more effective (first, second or third-
line treatment? Single or combined therapy? Combined 
chemotherapy or radiotherapy?); (II) the combination of two 
kinds of immune checkpoint inhibitors has been recently 
adopted in the treatment of advanced melanoma (20): 
does this treatment have the same effects also in NSCLC? 
Even with these problems still unresolved, the immune 
checkpoint inhibitors will revolutionize the future clinical 
practice of lung cancer, since these agents do not directly 
target and destroy the neoplastic cells but reactivate a 
patient’s own immune system to target cancer cells, and, 
therefore, their toxicity is generally mild. Trials that include 
anti-PD-1 immune checkpoint inhibitor in the standard 
treatment of locally advanced NSCLC (21) with the aim 
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to improve patient’s overall survival, progression-free 
survival as well as quality of life and other patient-reported 
outcomes are therefore welcome. Physicians also await the 
results of long-term follow-up of large cohort of patients 
treated with immune checkpoint inhibitors, to confirm that 
the initial survival advantage could translate in an acceptable 
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